A randomized, controlled, multicentre clinical study of Shengu Capsule in the treatment of postmenopausal osteoporosis (deficiency syndrome of liver and kidney)

Status

Active, not recruiting

Phases

Phase 4

Study type

Interventional

Source

ITMCTR

Registry ID

ITMCTR2100004996

Enrollment

Unknown

Registered

2021-06-28

Start date

2021-06-28

Completion date

Unknown

Last updated

2023-02-20

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Postmenopausal Osteoporosis

Interventions

Experimental group:Shengu Capsule

Control group:Calcium acetate Capsule

Eligibility

Sex/Gender

Female

Age

45 Years to 70 Years

Inclusion criteria

Inclusion criteria: 1.Meet the diagnostic criteria for postmenopausal osteoporosis; 2.Meet the TCM syndrome differentiation standard of liver and kidney deficiency; 3.Voluntarily signed informed consent; 4.Age between 45 and 70 years old; 5.Female have been naturally menopausal for more than 1 yearr.

Exclusion criteria

Exclusion criteria: 1.Those with secondary osteoporosis such as hyperparathyroidism, rheumatoid arthritis, multiple myeloma, type I diabetes, etc; 2.People with mental illness or Alzheimer's; 3.People with allergies or those who are known to be allergic to the ingredients in this medicine; 4.Those who are in a critical condition and are difficult to make an accurate assessment of the effectiveness and safety of the drug; 5.Patients with hypercalcemia and hypercalciuria.

Design outcomes

Primary

Measure	Time frame
Individual symptom score;VAS;TCM syndrome integral;25(OH)D;ALP;	—

Countries

China

Contacts

Public ContactGe Jirong

Fujian Academy of Chinese Medical Sciences

gjrrjgcy@163.com+86 13706957292

Outcome results

None listed

Source: ITMCTR (via WHO ICTRP) · Data processed: Feb 4, 2026